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Abstract:
Introduction:
Interleukin-33  (IL-33)  is  a  cell  damage-induced  alarmin.  The  plasma concentration  of  suppression  of  tumorogenicity  (sST2),  a
surrogate marker of IL-33 production, is a prognostic marker of cardiovascular disease.
Observation:
Recently,  we  reported  that  sST2  plasma  levels  were  elevated  in  early  HIV-1  infection  and  linked  to  markers  of  microbial
translocation and of T cell activation.
Results:
Here we show that it is not the case in patients with suppressed viremia. Thus, IL-33 plays its alarmin role only during the early
phase of the infection.
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INTRODUCTION
Interleukin-33 (IL-33), which is a member of the interleukin-1 (IL-1) cytokine family, is produced in response to the
cell damage caused by infections or by breaches in tissue barrier integrity [1]. The soluble form of the IL-33 cognate
receptor,  suppression  of  tumorogenicity  (sST2),  acts  as  a  decoy  receptor;  the  plasma  concentration  of  sST2  is  a
surrogate marker of IL-33 production and a prognostic marker of sepsis, acute respiratory distress, and of heart failure
[1]. Recently, we reported that sST2 plasma levels were elevated in early HIV-1 infection [2]. Furthermore, sST2 levels
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correlated with the levels of intestinal-type fatty acid-binding protein (I-FABP), a marker of epithelial gut damage. We
also found a correlation between plasma sST2 concentrations and the following markers of immune activation: CD8+
T-cell count, percentage of HLA-DR+CD38+CD4+ T-cells, percentage of HLA-DR+CD38+CD8+ T-cells, percentage
of PD-1 CD4+ T-cells, soluble CD14 (sCD14), soluble CD40L, interferon-γ, and plasma indoleamine-2,3-dioxygenase
activity. In the recent ACTIVIH study, we analyzed 68 markers of residual immune activation in 120 aviremic, HIV-1-
infected adults treated with antiretroviral therapy [3]. We decided to measure this cohort’s plasma sST2 concentrations.
METHODOLOGY
sST2 concentrations were determined by ELISA (Quantikine ELISA kit, R&D Systems) in stored, frozen plasma.
sST2 concentrations were compared using unpaired two-tailed t test.
Findings
The 120 virologic responders we analyzed were mostly male (82%) and Caucasians (95%). Their duration of viral
suppression  (mean  ±  SD)  was  102  ±  47  months,  for  a  duration  of  infection  of  17.2  ±  7.4  years.  Their  current  and
pretherapeutic CD4 counts were 688 ± 326 and 192 ± 108 cells/μL, respectively. Almost all of them were infected by
cytomegalovirus (91%) and Epstein-Barr virus (98%), and only 5% by Hepatitis C virus. Consistent with our previous
findings [2] and with those of Secemsky et al.  [4],  we found no difference in plasma sST2 concentrations between
effectively-treated  HIV-1-infected  adults  and  age-  and  sex-matched  healthy  controls  (Fig.  1a).  Although  the
concentration of sST2 was higher in untreated patients, this difference was not statistically significant (10.7 ± 1.0 and
9.7  ±  0.3  ng/mL,  respectively,  p  =  0.42).  sST2  plasma  levels  were  not  linked  to  the  duration  of  viral  suppression
(Pearson r < 0.01, p = 0.93).
We subsequently looked for a link between plasma sST2 concentration and markers of causes of immune activation.
Residual viremia, coinfections, microbial translocation, immune senescence and Treg deficiency have been identified as
potential drivers of persistent immune activation in virologic responders [5]. We failed to find a correlation between
plasma sST2 levels and i) residual viremia below 50 copies/mL or with frequency; ii) markers of senescence on CD4+
or CD8+ T-cells (CD27, CD28 and CD57) or on NK cells (CD57); iii) cytomegalovirus, Epstein-Barr virus, hepatitis A
virus, hepatitis B virus, and/or hepatitis C virus coinfections; iv) the plasma concentrations of bacterial DNA, I-FABP
or lipopolysaccharide-binding protein or v) the percentage of Treg cells. Furthermore, there was no correlation between
plasma sST2 concentration and smoking tobacco.
We also looked for correlations between plasma sST2 levels and the phenotype of the immune activation observed
in these patients. In the ACTIVIH study, a double hierarchical clustering of the 68 markers of immune activation and of
the  120 patients  resulted  in  the  identification  of  5  patient  groups  presenting  with  very  different  immune activation
profiles  [3].  This  means  that  patients  belonging  to  the  same  profile  have  common  marks  of  immune  activation  as
determined by the 68 markers we used. Looking for differences in sST2 levels among these immune activation profiles,
we observed that patients with profiles 2, 3, and 4 tended to have higher sST2 concentrations than the group consisting
of participants with profiles 1 or 5 (9.5 ± 0.4 and 8.5 ± 0.5 ng/mL, respectively, p = 0.11; Fig. 1b). Of note, immune
activation profile 2, which we previously showed to be strongly linked to an atherothrombosis-associated metabolic
syndrome [3], correlated with a high sST2 concentration, which is prognostic of cardiovascular disease [6]. In line with
our previous observation of a link between sST2 concentration and CD8+ T-cell count in early HIV-1 infection [2], we
found here that chronically infected patients with immune activation profiles 2, 3 and 4 presented with higher CD8+ T-
cell counts than patients with immune activation profiles 1 and 5 (p = 0.02; Fig. 1c).
We also looked for correlations between plasma sST2 levels and each of the 68 activation markers. No correlation
was observed between plasma sST2 levels and i) CD4+ or CD8+ T-cell differentiation (naïve/central memory/effector
memory),  CD4+  T-cell  activation  (HLA-DR  and/or  CD38),  CD4+  or  CD8+  T-cell  exhaustion  (PD-1);  ii)  NK  cell
activation (HLA-DR and/or CD69) or dysfunction (loss of CD56 expression); iii) B cell activation (IgG, IgA, and IgM
plasma levels);  iv)  monocyte  activation  (sCD14,  sCD163);  v)  neutrophil  activation  (CD64,  PD-L1,  loss  of  CD62L
expression);  vi)  inflammation  (CRP,  soluble  TNF  receptor  I);  vii)  endothelial  cell  activation  (tissue  plasminogen
activator, soluble endothelial protein C receptor and thrombomodulin); and viii) fibrinolysis (D-dimer). However, we
found a link between sST2 levels and the number of CD8+ T-cells expressing the activation marker HLA-DR (Pearson
r = 0.19, p = 0.03 ; Fig. 1d). This is illustrated in Fig. (1e) by the difference in HLA-DR+CD8+ T cell count in two
patients presenting with sST2 plasma levels of 15.7 and 1.0 ng/mL, respectively.
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Fig. (1). Plasma sST2 concentrations during chronic HIV-1 infection. (a) Plasma sST2 concentrations in uninfected controls, and
in  treated  or  untreated,  chronically  infected  adults.  (b)  Plasma  sST2  concentrations  in  chronically  infected  adults  with  various
immune activation profiles. (c) CD8+ T-cell count of patients presenting with various immune activation profiles. (d) Correlation
between plasma sST2 concentration and the number of circulating CD8+ T-cells expressing CD38. (e) HLA-DR expression on CD8+
T cells from patients with sST2 levels of 15.7 (upper plot) and 2.7 (lower plot) ng/mL.
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CONCLUSION
Collectively, our data showed that sST2 is mostly increased during early infection. HIV-induced gut barrier damage
is major at this stage, being partly reduced under antiretroviral therapy [7]. IL-33 is produced by damaged endothelial
and epithelial cells at this barrier site [1]. Accordingly, we observed a high sST2 peripheral blood concentration, linked
to the levels of the microbial translocation markers I-FABP and sCD14 in early HIV infection [2]. It is thus logical that
circulating sST2 levels are higher during the initial phase than during the treated chronic phase of the infection. IL-33
signaling via ST2 inhibits the development of atherosclerosis, and therefore, sST2 is thought to be proatherogenic [8].
Consequently, a slight sST2 overproduction in treated HIV patients, over years, might favour atherothrombosis. This
could explain why sST2 level is a predictor of cardiovascular insufficiency in HIV patients aviremic under treatment [4]
as it is in non-infected adults [6].
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